Cipla Share Price
Large Cap | Pharmaceuticals and health care | NSE: CIPLA | BSE: 500087
₹1,415.25 -80.45 (-5.38 %)
Last Updated: 04 Apr 2025 03:59 PM
Overview
Open (₹) 1,495.70
High (₹) 1,495.70
Low (₹) 1,390.05
Prev. Close (₹) 1,495.70
Volume 27,68,440
VWAP (₹) 1,416.07
ROCE (%) 21.79
Industry P/E 46.49
TTM P/E 22.91
P/B Ratio 4.26
Market Cap (₹) Cr.1,14,298.01
Dividend Yield (%)0.92
EPS (₹) 51.01
ROE15.37%
Sales Growth (%) 13.28
Profit Growth (%)46.55
Day Range
1,495.701,495.70
52 Week Range
1,317.601,702.00
Historical Returns
Returns (6M)
-12.89 %
Returns (1Y)
-3.04 %
Returns (3Y)
38.55 %
Returns (5Y)
187.51 %
Returns (6M)
-12.89 %
Returns (1Y)
-3.04 %
Returns (3Y)
38.55 %
Returns (5Y)
187.51 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Company with (47.05%) TTM EPS Growth
- Company with Low Debt
- Book value per share improving over the last 2 years
- Efficient in managing Assets to generate Profits - ROA improved since last year
- Company with 47.05% positive TTM EPS growth
- Increasing Annual Revenue for Past 2 Years
- Growth in Net Profit Margin (QoQ)
- Increasing Revenue every Quarter for the past 4 Quarters
Technicals
Technical Rating
RSI 46.85
MFI 32.40
ATR 34.23
Commodity Channel Index -193.59
ROC125 -13.04
ROC21 -3.43
Williams %R -92.65
Resistance & Support
Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
---|---|---|---|---|---|---|---|
Current | 1,437.46 | 1,467.43 | 1,486.16 | 1,418.73 | 1,388.76 | 1,370.03 | 1,340.06 |
Week Ago | 1,495.61 | 1,515.48 | 1,528.96 | 1,482.13 | 1,462.26 | 1,448.78 | 1,428.91 |
Month Ago | 1,473.70 | 1,526.80 | 1,580.60 | 1,419.90 | 1,366.80 | 1,313.00 | 1,259.90 |
EMA & SMA
1415.25
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
20
5 Day 1460.52
9 Day 1465.16
10 Day 1461.91
12 Day 1460.28
14 Day 1460.96
20 Day 1455.68
26 Day 1448.44
50 Day 1464.96
100 Day 1496.29
200 Day 1519.18
Deals & Announcements
Bulk and Block Deals
Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
---|---|---|---|---|---|---|
SAMINA HAMIED | block | Sell | 02 Dec, 2024 | ₹1,518.75 | 89,54,750 | NSE |
RUMANA HAMIED | block | Sell | 02 Dec, 2024 | ₹1,518.75 | 49,43,250 | NSE |
UBS PRINCIPAL CAPITAL ASIA LIMITED | block | Buy | 02 Dec, 2024 | ₹1,518.75 | 1,39,082 | NSE |
TATA AIA LIFE INSURANCE COMPANY LIMITED | block | Buy | 02 Dec, 2024 | ₹1,518.75 | 3,22,676 | NSE |
SOCIETE GENERALE | block | Buy | 02 Dec, 2024 | ₹1,518.75 | 2,16,967 | NSE |
SBI LIFE INSURANCE COMPANY LIMITED | block | Buy | 02 Dec, 2024 | ₹1,518.75 | 6,11,969 | NSE |
NORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBAL | block | Buy | 02 Dec, 2024 | ₹1,518.75 | 2,22,533 | NSE |
MOTILAL OSWAL MUTUAL FUND | block | Buy | 02 Dec, 2024 | ₹1,518.75 | 1,39,801 | NSE |
MORGAN STANLEY ASIA SINGAPORE PTE | block | Buy | 02 Dec, 2024 | ₹1,518.75 | 2,44,784 | NSE |
MONETARY AUTHORITY OF SINGAPORE | block | Buy | 02 Dec, 2024 | ₹1,518.75 | 3,78,482 | NSE |
SAMINA HAMIED | bulk | Sell | 02 Dec, 2024 | ₹1,518.75 | 89,54,750 | NSE |
RUMANA HAMIED | bulk | Sell | 02 Dec, 2024 | ₹1,518.75 | 49,43,250 | NSE |
SHIRIN HAMIED | bulk | Sell | 15 May, 2024 | ₹1,345.00 | 63,63,000 | NSE |
SAMINA HAMIED | bulk | Sell | 15 May, 2024 | ₹1,345.00 | 89,54,750 | NSE |
RUMANA HAMIED | bulk | Sell | 15 May, 2024 | ₹1,345.00 | 49,43,250 | NSE |
ICICI PRUDENTIAL MUTUAL FUND | bulk | Buy | 15 May, 2024 | ₹1,345.00 | 55,25,999 | NSE |
Insider Trading
Date | Name | Action | Avg. Price | Quantity | Deal Value |
---|---|---|---|---|---|
22 Aug, 2024 | Anusha Jain | Disposal | ₹1,590.83 | 2,000 | NSE |
14 Aug, 2024 | Anusha Jain | Disposal | ₹1,587.95 | 3,000 | NSE |
18 Oct, 2023 | Priyanka Mallick | Acquisition | ₹1,273.28 | 500 | NSE |
18 Oct, 2023 | Jaideep Mallick | Acquisition | ₹1,269.80 | 150 | NSE |
18 Oct, 2023 | Priyanka Mallick | Acquisition | ₹1,186.68 | 200 | NSE |
13 Apr, 2023 | Vidya Prabhakar Rote jointly with Kiran Rote | Acquisition | ₹1,110.38 | 1,000 | NSE |
13 Apr, 2023 | Vidya Prabhakar Rote jointly with Kiran Rote | Revoke | ₹1,075.90 | 1,000 | NSE |
13 Apr, 2023 | Vidya Prabhakar Rote jointly with Kiran Rote | Pledge | ₹1,119.15 | 1,000 | NSE |
05 Apr, 2023 | Shachi Malpani | Pledge | ₹965.95 | 10,000 | NSE |
05 Apr, 2023 | Shachi Malpani | Acquisition | ₹1,021.95 | 10,000 | NSE |
Corporate Actions
Announcement Date | Subject | Ex - Date | Record Date |
---|---|---|---|
10 May, 2024 | Rs.13.0000 per share(650%)Final Dividend | 02 Aug, 2024 | 02 Aug, 2024 |
12 May, 2023 | Rs.8.5000 per share(425%)Final Dividend | 21 Jul, 2023 | 21 Jul, 2023 |
27 Jul, 2022 | Rs.5.0000 per share(250%)Dividend | 08 Aug, 2022 | 10 Aug, 2022 |
Announcements
Date | Source | Detail |
---|---|---|
19 Mar, 2025 | NSE India | CIPLA LIMITED has informed the Exchange regarding Allotment of Securities |
19 Mar, 2025 | NSE India | Cipla Limited has informed the Exchange regarding Allotment of 2179 Shares. |
19 Mar, 2025 | BSE India | In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 19th March, 2025 has allotted 2,179 fully paid up equity shares of INR 2 each pursuant to exercise of employee stock options/stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company. |
20 Feb, 2025 | BSE India | USFDA inspection at analytical testing facility of Sitec Labs Limited in Mahape, Navi Mumbai, India |
20 Feb, 2025 | NSE India | Cipla Limited has informed the Exchange regarding ''USFDA inspection at analytical testing facility of Sitec in Mahape, Navi Mumbai, India''. |
20 Feb, 2025 | NSE India | Cipla Limited has informed the Exchange about Product launch |
20 Feb, 2025 | BSE India | Company has received final approval from USFDA for NDA submitted for Nilotinib Capsules 50, 150 and 200 mg on 19th February, 2025 |
19 Feb, 2025 | NSE India | Cipla Limited has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL |
18 Feb, 2025 | NSE India | Cipla Limited has informed the Exchange about General Updates |
18 Feb, 2025 | NSE India | Cipla Limited has informed the Exchange about Investor Presentation |
Board Meetings
Purpose | Details | Meeting Date | Broadcast Date |
---|---|---|---|
Quarterly Results | -- | 07 Jan, 2025 | 28 Jan, 2025 |
Quarterly Results | -- | 03 Oct, 2024 | 29 Oct, 2024 |
Quarterly Results | -- | 05 Jul, 2024 | 26 Jul, 2024 |
Audited Results & Final Dividend | -- | 08 Apr, 2024 | 10 May, 2024 |
Quarterly Results | -- | 21 Jan, 2024 | 25 Jan, 2024 |
Quarterly Results | (Revised) | 21 Jan, 2024 | 22 Jan, 2024 |
Quarterly Results | -- | 05 Oct, 2023 | 27 Oct, 2023 |
Quarterly Results | -- | 05 Jul, 2023 | 26 Jul, 2023 |
Audited Results & Final Dividend | -- | 13 Apr, 2023 | 12 May, 2023 |
Quarterly Results | -- | 30 Dec, 2022 | 25 Jan, 2023 |
Share Holding Pattern
Owner Name | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
---|---|---|---|---|---|
Promoter Group | 29.19% | 33.47% | 33.61% | 36.11% | 36.7% |
Foreign Institutions + | 26.65% | 25.73% | 28.39% | 24.35% | 22.08% |
Domestic Institutions + | 27.72% | 24.33% | 21.12% | 21.52% | 17.95% |
Government | 0% | 0% | 0% | 0% | 0% |
Public | 16.44% | 16.47% | 16.88% | 18.02% | 23.27% |
Others | 0% | 0% | 0% | 0% | 0% |
About Cipla
Cipla is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 16574.34 Cr. and Equity Capital is Rs. 161.47 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Cipla Group
Founded
1935
Managing Director
Mr. Umang Vohra
NSE Symbol
CIPLA
Cipla Management
Name | Designation |
---|---|
Dr. Y K Hamied | Chairman |
Mr. M K Hamied | Vice Chairman |
Mr. Umang Vohra | Managing Director & Global CEO |
Ms. Samina Hamied | Non Exe.Non Ind.Director |
Mr. S Radhakrishnan | Non Exe.Non Ind.Director |
Mr. Ashok Sinha | Independent Director |
Mr. P R Ramesh | Independent Director |
Mr. Robert Stewart | Independent Director |
Dr. Mandar Vaidya | Independent Director |
Mr. Adil Zainulbhai | Independent Director |
Ms. Punita Lal | Independent Director |
Dr. Balram Bhargava | Independent Director |
Peer Comparison
Stocks | Market Cap | Market Price | 52 Week Low-High |
---|---|---|---|
Sun Pharmaceutical Industries | ₹4,24,682.29 | ₹1,709.35 ₹1,770.00(-3.43%) | ₹1,376.750 - ₹1,960.200 |
Divi's Laboratories | ₹1,52,989.54 | ₹5,482.85 ₹5,763.00(-4.86%) | ₹3,556.300 - ₹6,448.750 |
Cipla | ₹1,20,795.29 | ₹1,415.25 ₹1,495.70(-5.38%) | ₹1,317.600 - ₹1,702.000 |
Torrent Pharmaceuticals | ₹1,09,916.93 | ₹3,286.50 ₹3,247.70(1.19%) | ₹2,508.650 - ₹3,589.950 |
Mankind Pharma | ₹1,00,161.69 | ₹2,451.20 ₹2,427.70(0.97%) | ₹1,910.100 - ₹3,050.000 |
FAQs on Cipla
What is the share price of Cipla?
The share price of Cipla on 04 Apr, 2025 is ₹ 1,415.25.
What is 52W high and 52W low share price of Cipla?
The highest and lowest 52W share prices of Cipla are ₹ 1702.000 and ₹ 1317.600
What is the market cap of Cipla?
The market capitalization of Cipla as of 04 Apr, 2025 is ₹ 1,14,298.01 Crores
What is the P/E ratio of Cipla?
The current P/E ratio of Cipla as of 04 Apr, 2025 is 46.49
What is the PB ratio of Cipla?
The PB ratio of Cipla as of 04 Apr, 2025 is 4.26
Top Gainers
₹109.04
₹90.87 (0.20%)
₹75.34
₹62.79 (0.20%)
₹143.15
₹119.30 (0.20%)
₹3.81
₹3.18 (0.20%)
Top Losers
₹3,206.90
₹3,774.25 (-0.15%)
₹28.50
₹32.80 (-0.13%)
₹950.60
₹1,188.25 (-0.20%)
₹753.20
₹889.55 (-0.15%)
Market Indices
Sensex
₹76,295.36
₹76,617.44 (0.00%)